Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OATD-02

Phase 1Small molecule

UUnknown Sponsor

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Ovarian CarcinomaRecruiting

Advanced Ovarian CarcinomaPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Advanced Ovarian Carcinoma

NCT05759923

Clinical

Trials by Indication[1]

Advanced Ovarian Carcinoma1 trial

An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours (Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer or Renal Cell Carcinoma)

Recruiting·UUnknown Sponsor·Phase 1·NCT05759923·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OATD-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OATD-02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OATD-02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUnknown Sponsor

Related News